Vasculotide, an angiopoietin-1 mimetic, reduces pulmonary vascular leakage and preserves microcirculatory perfusion during cardiopulmonary bypass in rats. – Vasomune Therapeutics

Vasculotide, an angiopoietin-1 mimetic, reduces pulmonary vascular leakage and preserves microcirculatory perfusion during cardiopulmonary bypass in rats.

Dekker NAM, van Meurs M, van Leeuwen ALI, Hofland HM, van Slyke P, Vonk ABA, Boer C, van den Brom CE. Br J Anaesth. 2018 Nov;121(5):1041-1051. doi: 10.1016/j.bja.2018.05.049. Epub 2018 Jun 19. PMID: 30336848

Dekker NAM, van Meurs M, van Leeuwen ALI, Hofland HM, van Slyke P, Vonk ABA, Boer C, van den Brom CE. Br J Anaesth. 2018 Nov;121(5):1041-1051. doi: 10.1016/j.bja.2018.05.049. Epub 2018 Jun 19. PMID: 30336848

About

Vasomune Therapeutics is a private biotechnology company developing Pegevongitide (AV-001), a first-in-class fully synthetic PEGylated peptide targeting the Tie2 receptor. Activation of the Tie2 receptor by Pegevongitide plays a critical role in improving vascular stability, barrier integrity and endothelial quiescence.

Vasomune Therapeutics 2025 © All Rights Reserved.